Primary outcome 1: Number of clinical recurrences per participant per year · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
1 finding from 1 review
Primary outcome 2: Clinical recurrence at 6 months · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
It is very uncertain whether oral drug treatment changes primary outcome 2: Clinical recurrence at 6 months compared with topical drug treatment (very low certainty).
1 finding from 1 review
Recurrence · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
It is very uncertain whether oral drug treatment changes primary outcome 2: Clinical recurrence at 12 months compared with topical drug treatment (very low certainty).
1 finding from 1 review
Primary outcome 3: Adverse events · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
1 finding from 1 review
Receipt of treatment for hypoglycaemia during initial hospital stay (investigator‐defined, any treatment ‐ oral dextrose gel, intravenous dextrose, or other drug therapy) during initial hospital stay (yes/no) · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in receipt of treatment for hypoglycaemia during initial hospital stay… compared with placebo (moderate certainty).
1 finding from 1 review
Time from beginning of treatment until death or full‐time ventilation · children with SMA types II and III
1 finding from 1 review
Adverse events related to treatment · children with SMA types II and III
1 finding from 1 review
Time from beginning of treatment until death or full‐time ventilation · non‐ambulatory children and adolescents with SMA types II and III
1 finding from 1 review
Adverse events related to treatment · non‐ambulatory children and adolescents with SMA types II and III
Oral olesoxime probably leads to lower adverse events related to treatment compared with placebo (moderate certainty).
1 finding from 1 review
Time from beginning of treatment until death or full‐time ventilation · adults with SMA types II and III
1 finding from 1 review
Adverse events related to treatment · adults with SMA types II and III
1 finding from 1 review
Time from beginning of treatment until death or full‐time ventilation · children and adults with SMA types II and III
1 finding from 1 review
Adverse events related to treatment · children and adults with SMA types II and III
1 finding from 1 review
Time from beginning of treatment until death or full‐time ventilation · ambulatory adults with SMA type III
1 finding from 1 review
no estimate extracted
33 participants
Low
Adverse events related to treatment · ambulatory adults with SMA type III
Oral valproic acid showed no clear difference in adverse events related to treatment compared with placebo (low certainty).
1 finding from 1 review
RR 0.8 [0.44, 1.44]
33 participants
Low
Time from beginning of treatment until death or full‐time ventilation · children with SMA type II
1 finding from 1 review
Adverse events related to treatment · children with SMA type II
Oral phenylbutyrate probably leads to higher adverse events related to treatment compared with placebo (moderate certainty).
1 finding from 1 review
Treatment success Fair, good or excellent effectiveness · Adults with lateral elbow pain
It is very uncertain whether oral NSAIDs changes treatment success Fair, good or excellent effectiveness compared with glucocorticoid injection (very low certainty).
1 finding from 1 review
Treatment success Fair, good or excellent effectiveness · Adults with lateral elbow pain
Oral NSAIDs showed no clear difference in treatment success Fair, good or excellent effectiveness compared with placebo (low certainty).
1 finding from 1 review
Time from beginning of treatment until death or full‐time ventilation · non‐ambulatory children with SMA types II and III
1 finding from 1 review